16 November 2022

---

Asep Inc. works with Bohai Biomedical to establish feasibility of peptide-based oral rinse

Katherine E. Pfaff

---

Asep Medical Holdings Inc. said the company has entered into a feasibility study agreement with Bohai Biomedical Technology Development Co. Ltd. The agreement will allow Bohai Biomedical to conduct a feasibility study using Asep Inc.'s proprietary anti-bacterial peptide as an active ingredient, according to a news release.

The peptide will be studied as an agent to mitigate and prevent erosive dental biofilm infections in an oral rinse product. The peptide technology has already been licensed from the University of British Columbia to Asep Inc.'s subsidiary, ABT Innovations. The agreement with Bohai Biomedical was signed in early October 2022, and the study was expected to enroll several thousand participants.

Fadia Saad, chief business officer of Asep Inc., noted in the release the exciting opportunities that exist in the Chinese dental market, proposed to be worth up to $17 billion by 2026.

The mouthwash had previously been tested at the UBC Department of Dentistry, with preliminary results that look promising in fighting difficult-to-treat oral biofilms.

About Asep Medical Holdings Inc. Asep Medical Inc. (asepmedical.com) is dedicated to addressing antibiotic failure by developing novel solutions for significant unmet medical needs. The Company is a consolidation of two existing private companies (Sepset Biosciences Inc. and ABT Innovations Inc.) that are both in the advanced development of both proprietary diagnostic tools, enabling the early and timely identification of severe sepsis as well as broad-spectrum therapeutic agents to address multidrug-resistant biofilm infections.